Simulations Plus Reports FY2020 and Fourth Quarter FY2020 Financial Results
Summary
We continue to invest in R&D, funded both internally and from leading pharmaceutical and regulatory agencies, building on our leadership position in modelling and simulation for the drug development marketplace.” John Kneisel, chief financial officer of Simulations Plus, added: “During the fourth quarter, we completed a strategic offering, issuing approximately 2.1 million shares and raising net proceeds of approximately $107.7 million. This follow-on offering gives the Company resources and scale to pursue additional acquisitions to further bolster our growth rates and broaden the value we can deliver to our clients. Overall, we continue to generate solid profitability and free cash flow, even after paying our regular quarterly dividend.” The Company invites all interested persons to attend its conference call at 4:15 p.m. Eastern Time on November 16, 2020. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide.
Classifications
AskAI Classifications
LabelsLinked Companies
